Brian T. Hess

Hematology
171 Ashley Ave
Charleston, SC 29425

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Journal: Future oncology (London, England)
Published: July 06, 2026

Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

Journal: Advances in therapy
Published: May 08, 2026

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.

Journal: Haematologica
Published: March 17, 2026

Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.

Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.

Journal: Annals of hematology
Published: January 09, 2026

Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

Journal: Blood
Published: July 02, 2025

Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.

Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.

Journal: Blood
Published: July 02, 2025

Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.

Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 16, 2025

Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.

Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.

Journal: Cancers
Published: May 28, 2025

Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.

Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.

Journal: Haematologica
Published: May 23, 2025

Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

Journal: Blood advances
Published: May 09, 2025

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

Journal: Blood advances
Published: April 24, 2025

Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.

Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.

Journal: Blood advances
Published: December 10, 2024
Showing 1-12 of 50

Last Updated: 09/26/2026